|
May 2
|
Mustang Bio Announces Closing of $4 Million Public Offering
|
|
May 1
|
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
|
|
Apr 30
|
Mustang Bio Announces Pricing of $4 Million Public Offering
|
|
Apr 29
|
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
|
|
Apr 25
|
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
|
|
Apr 24
|
Avenue Therapeutics Announces Reverse Stock Split
|
|
Mar 28
|
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
|
|
Mar 28
|
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
|
|
Mar 25
|
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
|
|
Mar 22
|
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
|
|
Mar 21
|
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
|
|
Mar 18
|
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
|
|
Mar 18
|
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
|
|
Mar 18
|
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
|
|
Mar 15
|
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
|
|
Mar 15
|
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
|
|
Mar 13
|
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
|
|
Mar 12
|
Fortress Biotech to Participate in 36th Annual ROTH Conference
|
|
Mar 11
|
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
|
|
Mar 11
|
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
|